March 2016

March 2016 TBBCF Newsletter

TBBCF Celebrates Women’s History Month Sharing stories of wonderful women via TBBCF social media Women ‘ s History Month is a celebration of women ‘ s contributions to worldwide culture and society. The United States has observed it annually throughout the month of March since 1987. We have asked various women involved with TBBCF – Board of Directors members,

March 2016 TBBCF Newsletter Read More »

TBBCF Visits DFCI Researcher

TBBCF Visits 2016 Grant Recipient, Daniel Stover, MD, at Dana-Farber Cancer Institute Members of the Terri Brodeur Breast Cancer Foundation visited Dana-Farber Cancer Institute to meet Daniel Stover, MD, one of our 2016 grant recipients. Pictured from left to right, are Daniel Stover, MD; John LaMattina, PhD, Co-Chair of the TBBCF Scientific Advisory Committee, Sandy

TBBCF Visits DFCI Researcher Read More »

TBBCF Visits MGH Researcher

TBBCF Visits 2016 Grant Recipient, Mihriban Karaayvaz, PhD, at Massachusetts General Hospital Cancer Center Another visit on March 17 by members of the Terri Brodeur Breast Cancer Foundation to Massachusetts General Hospital to meet Mihriban Karaayvaz, PhD, one of our 2016 grant recipients. Pictured from left to right are John LaMattina, PhD, Co-Chair TBBCF Scientific

TBBCF Visits MGH Researcher Read More »

The Day Editorial on TBBCF

Brodeur Foundation marks 10 years of bringing good from tragedy. Published March 15, 2016 6:57PM. The Day The success of the Terri Brodeur Breast Cancer Foundation is proof that out of great tragedy can come great good. Breast cancer killed Terri Brodeur in 2005, her 41st year, leaving behind three children and a husband. Before

The Day Editorial on TBBCF Read More »

Eneda Toska, PhD

Eneda Toska, PhD Memorial Sloan Kettering Cancer Center Mutations in the PIK3CA gene are the most frequent genomic alterations in estrogen receptor (ER)-positive breast cancers. One treatment strategy is the use of drugs that inhibit the gene’s signaling pathway—however, many patients eventually become resistant to this type of therapy. Further, PI3K signaling pathway inhibition has

Eneda Toska, PhD Read More »

Daniel G. Stover, MD

Daniel G. Stover, MD Dana-Farber Cancer Institute The host immune system is critical in the control and elimination of tumors in many cancer types. In breast cancer, tumor infiltrating immune cells have been associated with both response to chemotherapy and overall outcome for patients. Understanding what immune cell populations infiltrate tumors may help guide which

Daniel G. Stover, MD Read More »

Mihriban Karaayvaz, PhD

Mihriban Karaayvaz, PhD Mass General Hospital Cancer Center Making a major impact on the incidence and lethality of breast cancer will require a detailed understanding of the early events in breast cancer development, particularly in women who are at the highest risk of developing these cancers such as those who carry mutations in the BRCA1/2

Mihriban Karaayvaz, PhD Read More »

Jean Albrengues, Ph.D.

Jean Albrengues, Ph.D. Ph.D. Cold Spring Harbor Laboratories Dr. Jean Albrengues’ 2016 Terri Brodeur Breast Cancer Foundation fellowship award focuses on the regulation of breast cancer dormancy by the tumor microenvironment. Metastatic breast cancer relapse occurring years after seemingly successful treatment is preceded by an interlude, termed dormancy when cancer remains non-proliferative and undetected at

Jean Albrengues, Ph.D. Read More »

Scroll to Top
Skip to content